BioSpace News Archive

The salary expectation question is one of the most difficult questions asked during a job interview. Here’s how you can answer the question perfectly.

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced it will host a live webcast on Tuesday, August 3, 2021 at 8:00 a.m. ET to announce second quarter 2021 financial results and discuss recent business updates.

BD, a leading global medical technology company, announced it has taken a large step forward in transforming the patient experience through a vision of a “One-Stick Hospital Stay,” building on its history of innovation and leadership in blood collection and vascular access solutions.

Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that Honorable Mark Dybul, M.D. has been named as Chief Executive Officer.

MESI, Ltd is pleased to announce that they have successfully added the certificate for conformance with ISO 13485:2016/MDSAP to their array of international certifications, including EC and FDA.

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced that it has completed a financing round of US$6.2 million led by AXA IM, through AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management1

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the creation of a new business unit, HTG Therapeutics.

Glympse Bio today announced the appointment of Matthew T. Navarro , J.D., to the newly-created role of Chief Financial Officer.

Longhorn Vaccines & Diagnostics, LLC, a privately held biotechnology company, announced publication of pre-clinical data on the company’s universal influenza vaccine candidate, LHNVD-105, which is a multi-epitope unconjugated influenza composite peptide formulated in collaboration with the U.S. Army’s Liposomal Adjuvant.

Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage via microbiome-driven liquid biopsy technology, announced a collaboration with the University of New South Wales, Sydney for a $4 million grant from the Australian Government to fund research into hepatocellular carcinoma, the most common type of primary liver cancer.